CN102631337A - Application of coenzyme Q10 to preparation of medicines for preventing and treating altitude erythrocytosis - Google Patents
Application of coenzyme Q10 to preparation of medicines for preventing and treating altitude erythrocytosis Download PDFInfo
- Publication number
- CN102631337A CN102631337A CN2012101361953A CN201210136195A CN102631337A CN 102631337 A CN102631337 A CN 102631337A CN 2012101361953 A CN2012101361953 A CN 2012101361953A CN 201210136195 A CN201210136195 A CN 201210136195A CN 102631337 A CN102631337 A CN 102631337A
- Authority
- CN
- China
- Prior art keywords
- coenzyme
- preparation
- erythrocytosis
- medicines
- altitude erythrocytosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses application of coenzyme Q10 to preparation of medicines for preventing and treating altitude erythrocytosis. Commercially available coenzyme Q10 is purchased, healthy men migrating from a plain to a plateau with an elevation of 4300m are tracked, and are given with the coenzyme Q10 for orally taking one grain once with three times for one day; the healthy men are administrated with the coenzyme Q10 before and after 1 month and two months, blood routine examination is detected, and data is subjected to statistical analysis by adopting SPSS13.0 independent samples T. According to the invention, the altitude erythrocytosis caused by long-term chronic hypoxia can be effectively prevented and treated, the hypoxia tolerance of a human body can be effectively improved, and the function of improving microcirculation is achieved.
Description
Technical field
The present invention relates to the new purposes of existing medicine, be specifically related to coenzyme Q10 and prevent and treat the application in the high altitude erythrocytosis medicine in preparation.
Background technology
Long-term chronic hypoxia can cause erythrocytosis, and this helps improving the oxygen carrying capacity of blood flow, improve tissue oxygen and supply, and be the effective compensatory response of organism adaptation environment of low oxygen plateau.But groups of people's erythrocyte overcompensation property hypertrophy, HC surpasses 200 g/L, RBC>=6.5 * 10
12/ L, packed cell volume>=65%, be called high altitude erythrocytosis [Li Suzhi chief editor. high altitude disease is learned, People's Health Publisher, 2006:70-71].Thereby packed cell volume is the important indicator of diagnosis high altitude erythrocytosis, and packed cell volume increases, and makes blood viscosity increase; Resistance of blood flow strengthens; Flow slowly, high blood coagulation state further increases the weight of histoorgan congestion, anoxia, forms a kind of vicious cycle.Clinical manifestation is many organs hypoxic damage, especially with the more internal organs of oxygen consumption: get involved like brain, the heart, lung, liver etc. and to attach most importance to.Sickness rate is 2.43% to the high altitude erythrocytosis sickness rate on the above plateau of height above sea level 3000 m, and increases the morbidity showed increased with height above sea level, is the commonly encountered diseases of highlands health risk, does not still have satisfied Therapeutic Method and medicine so far.
Coenzyme Q10 is an essential composition of forming respiratory chain in the body; It is the hydrogen carrier in the electron transport chain; Participate in the synthetic of ATP (ATP); Being mainly derived from food replenishes with self synthetic; Be one of antioxidant the strongest in the present known body [Singh RB. Effect of coenzyme Q10 on experimental atherosclerosis and chemical composition and quality of atheroma in rabbits. Atherosclerosis. 2000,148:275-282].Coenzyme Q10 is mainly derived from meat, fowl, fish and some vegetable in the meals, like curd (broccoli), Brassica oleracea L. var. botrytis L. (cauliflower) etc.Coenzyme Q10 is effective anti-oxidants and free radical scavenger; It is embedded in the mitochondrial inner membrane lipid bimolecular as the ingredient of mitochondrial respiratory chain; Behind 2 electronics of mitochondrion complex I or the acceptance of complex II, become pure formula, give complex III with electron transport again.The body coenzyme Q 10 is become pure formula by lot of consumption, and it is an effective anti-oxidants, also is the ELECTRON OF MOTION carrier simultaneously, and it is given to the lipid peroxidation free radical with hydrogen atom from its hydroxyl, thereby reduces the MDA reaction of mitochondrial inner membrane.In this process, generated and the out-of-proportion free radical ubisemiquinone of the pure formula of coenzyme Q10 and coenzyme Q10; Or with the oxygen formation superoxides that reacts; The free radical ubisemiquinone is transported free radical and is realized Detoxication under superoxide dismutase and catalatic effect; So move in circles; Mitochondrial respiratory chain has recovered its antioxidant activity effect [Tran UC. Endogenous synthesis of coenzyme Q in eukaryotes. Mitochondrion. 2007, Suppl:S62-71] with the continuous regeneration alcohol of coenzyme Q10 formula.Coenzyme Q10 is widely used in the middle of the auxiliary treatment of diseases such as alzheimer disease, parkinson disease, cardiomyopathy and aging at present; Safe and effective; Be fit to life-time service [Scarpelli M. Current options in the treatment of mitochondrial diseases.Recent Pat CNS Drug Discov. 2010,5:203-209].Research shows that coenzyme Q10 has different physiological roles, reduces the oxidative damage that anoxia causes, the prompting coenzyme Q10 possibly become a kind of effective anoxia enduring medicine, but the relevant effect that it prevents and treats high altitude erythrocytosis is not all appeared in the newspapers the home and abroad so far.
Summary of the invention
The purpose of this invention is to provide a kind of new purposes of coenzyme Q10, promptly coenzyme Q10 is prevented and treated the application in the high altitude erythrocytosis medicine in preparation, and it can effectively reduce erythrocytosis due to the long-term chronic hypoxia, and microcirculation improvement is taken for a long time and had no side effect.
Coenzyme Q10 of the present invention is prevented and treated the application in the high altitude erythrocytosis medicine in preparation, it is characterized in that: buy commercially available coenzyme Q10 (Shanghai Xudong Hipu Medicine Co., Ltd), 10 mg/ grains.
Human experimentation proves: migrate height above sea level 4300 m plateau healthy males from the Plain; Give coenzyme Q 10 oral, each 1, every day 3 times; Before taking medicine; Take medicine after January and February, measure routine blood test, the result finds that packed cell volume is starkly lower than packed cell volume in the placebo group blood in the administration group blood.
This experiment obtains experimenter's the informed consent and the agreement of Ethics Committee of Military Medical Univ No.3, P.L.A.
The effect that the present invention is useful: coenzyme Q10 can be prevented and treated erythrocytosis due to the long-term chronic hypoxia with imitating, can effectively improve body anoxia toleration, and have the effect of microcirculation improvement.
The specific embodiment
Coenzyme Q10 of the present invention is prevented and treated the application in the high altitude erythrocytosis medicine in preparation, buys commercially available coenzyme Q10, and height above sea level 4300 m plateau healthy males are migrated in tracking from the Plain; Give coenzyme Q 10 oral; Each 1, every day 3 times, respectively before administration, after administration January and February; Detect routine blood test, the independent sample T of The data SPSS13.0 carries out statistical analysis.
Human trial process and result are following:
Coenzyme Q10 is migrated the influence of height above sea level 4300 m plateau male's packed cell volumes
At height above sea level 1300 m, to select to intend the male of Han nationality who migrates plateau (4300 m) and be divided into coenzyme Q10 group (18 people) and placebo group (20 people) at random, the coenzyme Q10 group gives coenzyme Q10 10 mg/ time (oral) continuously, and 3/d takes February continuously; Matched group (being placebo group) is taken placebo 10 mg/ time (placebo is a flour) simultaneously.Before taking medicine, take medicine January respectively, get vein the February of taking medicine after, extracting vein blood, the SwelabAC-910EO+ routine blood test analyzer that adopts Sweden to produce is measured routine blood test.The result finds, give after coenzyme Q 10 oral January and February that packed cell volume significantly reduces in the blood (P 0.05) and placebo group (P>0.05) (table 3).
Claims (1)
1. coenzyme Q10 is prevented and treated the application in the high altitude erythrocytosis medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101361953A CN102631337A (en) | 2012-05-04 | 2012-05-04 | Application of coenzyme Q10 to preparation of medicines for preventing and treating altitude erythrocytosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101361953A CN102631337A (en) | 2012-05-04 | 2012-05-04 | Application of coenzyme Q10 to preparation of medicines for preventing and treating altitude erythrocytosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102631337A true CN102631337A (en) | 2012-08-15 |
Family
ID=46616020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101361953A Pending CN102631337A (en) | 2012-05-04 | 2012-05-04 | Application of coenzyme Q10 to preparation of medicines for preventing and treating altitude erythrocytosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102631337A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105193839A (en) * | 2015-10-29 | 2015-12-30 | 常州亚当生物技术有限公司 | Preparation for resisting altitude sickness and application of preparation |
| CN114209834A (en) * | 2021-05-07 | 2022-03-22 | 中国人民解放军军事科学院军事医学研究院 | Application of MCUR1 as biomarker of altitude erythrocytosis and method for screening medicine |
-
2012
- 2012-05-04 CN CN2012101361953A patent/CN102631337A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| IKEMATSU, HIDEYUKI 等: "Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: A double-blind, randomized, placebo-controlled trial.", 《REGULATORY TOXICOLOGY AND PHARMACOLOGY》 * |
| 彭亮等: "辅酶Q10提高小鼠抗疲劳和耐缺氧能力的实验研究", 《中国卫生检验杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105193839A (en) * | 2015-10-29 | 2015-12-30 | 常州亚当生物技术有限公司 | Preparation for resisting altitude sickness and application of preparation |
| CN114209834A (en) * | 2021-05-07 | 2022-03-22 | 中国人民解放军军事科学院军事医学研究院 | Application of MCUR1 as biomarker of altitude erythrocytosis and method for screening medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Galli et al. | Oxidative stress and antioxidant therapy in cystic fibrosis | |
| Lee et al. | Antiinflammatory effects of L-carnitine supplementation (1000 mg/d) in coronary artery disease patients | |
| McDonagh et al. | The effects of chronic nitrate supplementation and the use of strong and weak antibacterial agents on plasma nitrite concentration and exercise blood pressure | |
| Takahashi et al. | Effects of curcumin supplementation on exercise-induced oxidative stress in humans | |
| Yue et al. | Effects of transport stress on blood metabolism, glycolytic potential, and meat quality in meat-type yellow-feathered chickens | |
| Gluhchevaa et al. | Sodium nitrite-induced hematological and hemorheological changes in rats | |
| Abdel-Tawwab et al. | Antioxidants and immune responses, resistance to Aspergilus flavus infection, and growth performance of Nile tilapia, Oreochromis niloticus, fed diets supplemented with yeast, Saccharomyces serevisiae | |
| Mandal et al. | In vivo assessment of bacteriotherapy on acetaminophen-induced uremic rats | |
| Lee et al. | Potential protective effects of fermented garlic extract on myocardial ischemia-reperfusion injury utilizing in vitro and ex vivo models | |
| Jones | The health dividend of glutathione | |
| Guthrie et al. | Multi-omic profiles of hepatic metabolism in TPN-fed preterm pigs administered new generation lipid emulsions | |
| CN102631337A (en) | Application of coenzyme Q10 to preparation of medicines for preventing and treating altitude erythrocytosis | |
| JP2016210720A (en) | Motor function improving agent, respiratory function improving agent, or cognitive ability improving agent | |
| Díaz-Castro et al. | Influence of several sources and amounts of iron on DNA, lipid and protein oxidative damage during anaemia recovery | |
| Wester et al. | Hepatic metabolism of 2-hydroxy-4-methylthiobutyrate in growing lambs | |
| Musthafa et al. | Ameliorative efficacy of bioencapsulated Chironomous larvae with Shilajit on Zebrafish (Danio rerio) exposed to Ionizing radiation | |
| Fujihara et al. | The effect of dietary vitamin E level on selenium status in rats | |
| Biobaku et al. | Effects of doses of ascorbic acid on physio-biochemical parameters of Sahel bucks exposed to stocking and 28–hour road transportation (North Western–South Western, Nigeria) | |
| EP2900252B1 (en) | Agent for enhancing immunity containing glutathione | |
| US20160158309A1 (en) | Exercise function enhancer | |
| Razi et al. | The Impact of oral CoQ10 supplementation on peripheral blood lipid profiles and muscular damage indices following two weeks intense aerobic training in elite cyclists | |
| Das et al. | Antioxidant effect of vitamin c on type 2 diabetes mellitus patients along with two different oral hypoglycemic agents for smooth glycemic control | |
| Finlayson et al. | The Effects of Iron Supplementation and Fortification on the Gut Microbiota: A Review | |
| Takahashi et al. | Oral administration of [ALPHA]-lipoic acid increases serum levels of ascorbic acid and tocopherol: A pilot hematological study | |
| RU2252773C1 (en) | Antihypoxic preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120815 |